The High Rate of Bone Resorption in Multiple Myeloma is due to RANK (Receptor Activator of Nuclear Factor-κB) and RANK Ligand Expression

Reference

• Bataille, R., Chappard, D., Marcelli, C., Dessauw, P., Baldet, P., Sany, J., et al. (1991) "Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma", Journal of Clinical Investigation, 88, 62— 66.
   Google Scholar
• Chappard, D., Rossi, J.F., Bataille, R. and Alexandre, C. (1991) "Osteoclast cytomorphometry demonstrates an abnormal popula-tion in B cell malignancies but not in multiple myeloma", Calcified Tissue International, 48, 13 — 17.
   Google Scholar
• Roodman, G.D. (1997) "Mechanisms of bone lesions in multiple myeloma and lymphoma", Cancer, 80, 1557–1563.
   Google Scholar
• Taube, T., Beneton, M.N., McCloskey, E.V., Rogers, S., Greaves, M. and Kanis, J.A. (1992) "Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption", European Journal of Haematology, 49, 192— 198.
   Google Scholar
• Yaccoby, S., Pearse, R.N., Johnson, C.L., Barlogie, B., Choi, Y. and Epstein, J. (2002) "Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity", British Journal of Haematology, 116, 278–290.
   Google Scholar
• Callander, N.S. and Roodman, G.D. (2001) "Myeloma bone disease", Seminars in Hematology, 38, 276–285.
   PubMed Web of Science ®Google Scholar
• Bataille, R., Chappard, D. and Klein, B. (1992) "The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma", International Journal of Clinical and Laboratory Research, 21, 283 — 287.
   Google Scholar
• Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M.T. and Martin, T.J. (1999) "Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families", Endocrine Reviews, 20, 345— 357.
   Google Scholar
• Hofbauer, L.C., Khosla, S., Dunstan, CR., Lacey, DL., Boyle, W.J. and Riggs, B.L. (2000) "The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorp-tion", Journal of Bone and Mineral Research, 15, 2 — 12.
   Google Scholar
• Quinn, J.M., Elliott, J., Gillespie, M.T. and Martin, T.J. (1998) "A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro", Endocrinology, 139, 4424–4427.
   Google Scholar
• Jimi, E., Akiyama, S., Tsurukai, T., Okahashi, N., Kobayashi, K., Udagawa, N., et al. (1999) "Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function", Journal of Immunology, 163, 434–442.
   Google Scholar
• Lacey, DL., Timms, E., Tan, H.L., Kelley, Mi., Dunstan, CR., Burgess, T., et al. (1998) "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation", Cell, 93, 165 — 176.
   Google Scholar
• Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Yano, K., et al. (1998) "RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis", Biochemical and Biophysical Research Communications, 253, 395 — 400.
   PubMed Web of Science ®Google Scholar
• Hsu, H., Lacey, D.L., Dunstan, C.R., Solovyev, I., Colombero, A., Timms, E., et al. (1999) "Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand", Proceedings of the National Academy of Sciences of the United States of America, 96, 3540 — 3545.
   Google Scholar
• Tsuda, E., Goto, M., Mochizuki, S., Yano, K., Kobayashi, F., Morinaga, T., et al. (1997) "Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis", Biochemical and Biophysical Research Communications, 234, 137 — 142.
   Google Scholar
• Simonet, W.S., Lacey, D.L., Dunstan, C.R., Kelley, M., Chang, M.S., Luthy, R., et al. (1997) "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density", Cell, 89, 309 — 319.
   Google Scholar
• Wittrant, Y., Couillaud, S., Theoleyre, S., Dunstan, C., Heymann, D. and Redini, F. (2002) "Osteoprotegerin differentially regulates protease expression in osteoclast cultures", Biochemical and Biophysical Research Communications, 293, 38–44.
   PubMed Web of Science ®Google Scholar
• Kong, Y.Y., Boyle, W.J. and Penninger, J.M. (2000) "Osteoprote-gerin ligand: a regulator of immune responses and bone physiol-ogy", Immunology Today, 21, 495–502.
   Google Scholar
• Takayanagi, H., Ogasawara, K., Hida, S., Chiba, T., Murata, S., Sato, K., et al. (2000) "T-cell-mediated regulation of osteoclasto-genesis by signalling cross-talk between RANKL and IFN-gamma", Nature, 408, 600–605.
   Google Scholar
• Lubberts, E., Joosten, L.A., Chabaud, M., van Den Bersselaar, L., Oppers, B., Coenen-De Roo, CJ., et al. (2000) "IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion", Journal of Clinical Investigation, 105, 1697 — 1710.
   PubMed Web of Science ®Google Scholar
• Wei, S., Wang, M.W., Teitelbaum, S.L. and Ross, F.P. (2002) "Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling", Journal of Biological Chemistry, 277, 6622–6630.
   PubMed Web of Science ®Google Scholar
• Kobayashi, K., Takahashi, N., Jimi, E., Udagawa, N., Takami, M., Kotake, S., et al. (2000) "Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/ RANKL-RANK interaction", Journal of Experimental Medicine, 191, 275–286.
   Google Scholar
• Kudo, 0., Sabokbar, A., Pocock, A., Itonaga, I., Fujikawa, Y. and Athanasou, N.A. (2003) "Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechan-ism", Bone, 32, 1–7.
   Google Scholar
• Roodman, G.D. (1992) "Interleukin-6: an osteotropic factor?", Journal of Bone and Mineral Research, 7, 475–478.
   PubMed Web of Science ®Google Scholar
• Giuliani, N., Bataille, R., Mancini, C., Lazzaretti, M. and Barille, S. (2001) "Myeloma cells induce imbalance in the osteoprotegerin/ osteoprotegerin ligand system in the human bone marrow environ-ment", Blood, 98, 3527–3533.
   Google Scholar
• Pearse, R.N., Sordillo, E.M., Yaccoby, S., Wong, B.R., Liau, D.F., Colman, N., et al. (2001) "Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression", Proceedings of the National Academy of Sciences of the United States of America, 98, 11581 — 11586.
   Google Scholar
• Roux, S., Meignin, V., Quillard, J., Meduri, G., Guiochon-Mantel, A., Fermand, J.P., et al. (2002) "RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma", British Journal of Haematology, 117, 86–92.
   PubMed Web of Science ®Google Scholar
• Giuliani, N., Colla, S., Sala, R., Moroni, M., Lazzaretti, M., La Monica, S., et al. (2002) "Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease", Blood, 100, 4615–4621.
   Google Scholar
• Sezer, 0., Heider, U., Jakob, C., Eucker, J. and Possinger, K. (2002) "Human bone marrow myeloma cells express RANKL", Journal of Clinical Oncology, 20, 353–354.
   PubMed Web of Science ®Google Scholar
• Sezer, 0., Heider, U., Jakob, C., Zavrski, I., Eucker, J., Possinger, K., et al. (2002) "Immunocytochemistry reveals RANKL expression of myeloma cells", Blood, 99, 4646–4647; discussion 4647.
   Google Scholar
• Terpos, E., Szydlo, R., Apperley, J.F., Hatjiharissi, E., Politou, M., Meletis, J., et al. (2003) "Soluble receptor activator of nuclear factor {kappa}13 ligand (RANKL)/osteoprotegerin (OPG) ratio predicts survival in multiple myeloma. Proposal for a novel prognostic index", Blood, 102, 1064 — 1069.
   Google Scholar
• Standal, T., Seidel, C., Hjertner, 0., Plesner, T., Sanderson, R.D., Waage, A., et al. (2002) "Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells", Blood, 100, 3002— 3007.
   Google Scholar
• Lipton, A., Ali, S.M., Leitzel, K., Chinchilli, V., Witters, L., Engle, L., et al. (2002) "Serum osteoprotegerin levels in healthy controls and cancer patients", Clinical Cancer Research, 8, 2306–2310.
   PubMed Web of Science ®Google Scholar
• Seidel, C., Hjertner, 0., Abildgaard, N., Heickendorff, L., Hjorth, M., Westin, J., et al. (2001) "Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease", Blood, 98, 2269–2271.
   PubMed Web of Science ®Google Scholar
• Cappellen, D., Luong-Nguyen, N.H., Bongiovanni, S., Grenet, 0., Wanke, C. and Susa, M. (2002) "Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B", Journal of Biological Chemistry, 277, 21971 —21982.
   Google Scholar
• Zhang, Y.H., Heulsmann, A., Tondravi, M.M., Mukherjee, A. and Abu-Amer, Y. (2001) "Tumor necrosis factor-alpha (TNF) stimu-lates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways", Journal of Biological Chemistry, 276, 563 — 568.
   Google Scholar
• Sezer, 0., Heider, U., Zavrski, I., Kuhne, C.A. and Hofbauer, L.C. (2003) "RANK ligand and osteoprotegerin in myeloma bone disease", Blood, 101, 2094–2098.
   PubMed Web of Science ®Google Scholar
• Choi, Si., Cruz, J.C., Craig, F., Chung, H., Devlin, R.D., Roodman, G.D., et al. (2000) "Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma", Blood, 96, 671 —675.
   Google Scholar
• Han, J.H., Choi, S.J., Kurihara, N., Koide, M., Oba, Y. and Roodman, G.D. (2001) "Macrophage inflammatory protein-lalpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand", Blood, 97, 3349 — 3353.
   Google Scholar
• Choi, S.J., Oba, Y., Gazitt, Y., Alsina, M., Cruz, J., Anderson, J., et al. (2001) "Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease", Journal of Clinical Investigation, 108, 1833–1841.
   Google Scholar
• Van Riet, I. (1999) "Homing mechanisms of myeloma cells", Pathologie Biologie (Paris), 47, 98 — 108.
   PubMed Web of Science ®Google Scholar
• Oyajobi, B.O. and Mundy, G.R. (2003) "Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1 alpha, and the proteasome", Cancer, 97, 813–817.
   PubMed Web of Science ®Google Scholar
• Roodman, G.D. (2002) "Role of the bone marrow microenviron-ment in multiple myeloma", Journal of Bone and Mineral Research, 17, 1921–1925.
   Web of Science ®Google Scholar
• Croucher, P.I., Shipman, CM., Lippitt, J., Perry, M., Asosingh, K., Wizen, A., et al. (2001) "Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma", Blood, 98, 3534 — 3540.
   Google Scholar
• Doran, P., Russel, Si., Chen, D., Greiner, S.M., Ludvigson, J., Khosla, S., et al. (2002) "Gene transfer of osteoprotegerin-Fc inhibits osteolysis and disease progression in a murine model of multiple myeloma", Journal of Bone and Mineral Research, 17\(suppl 1), S147.
   Google Scholar
• Oyajobi, B.O., Garrett, I.R., Williams, P.J., Yoneda, T., Anderson, D.M. and Mundy, G.R. (2000) "A soluble murine receptor activator of nuclear factor kappaB-human Immunoglobulin fusion protein (RANK: Fe) inhibits bone resorption in a murine model of human multiple myeloma bone disease", Journal of Bone and Mineral Research, 15\(suppl 1), S176.
   Web of Science ®Google Scholar
• Body, Li., Greipp, P., Coleman, RE., Facon, T., Geurs, F., Fermand, J.P., et al. (2003) "A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases", Cancer, 97, 887–892.
   PubMed Web of Science ®Google Scholar
• Vanderkerken, K., De Leenheer, E., Shipman, C., Asosingh, K., Willems, A., Van Camp, B., et al. (2003) "Recombinant osteopro-tegerin decreases tumor burden and increases survival in a murine model of multiple myeloma", Cancer Research, 63, 287–289.
   Google Scholar
• Emery, J.G., McDonnell, P., Burke, MB., Deen, K.C., Lyn, S., Silverman, C., et al. (1998) "Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL", Journal of Biological Chemistry, 273, 14363 — 14367.
   PubMed Web of Science ®Google Scholar
• Gazitt, Y. (1999) "TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells", Leukemia, 13, 1817–1824.
   Web of Science ®Google Scholar
• Mitsiades, CS., Treon, S.P., Mitsiades, N., Shima, Y., Richardson, P., Schlossman, R., et al. (2001) "TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications", Blood, 98, 795–804.
   PubMed Web of Science ®Google Scholar
• Lincz, L.F., Yeh, T.X. and Spencer, A. (2001) "TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy", Leukemia, 15, 1650–1657.
   Web of Science ®Google Scholar
• Ni, H., Ergin, M., Huang, Q., Qin, J.Z., Amin, H.M., Martinez, R.L., et al. (2001) "Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis", British Journal of Haematology, 115, 279–286.
   PubMed Web of Science ®Google Scholar
• Mitsiades, N., Mitsiades, CS., Poulaki, V., Chauhan, D., Richard-son, PG., Hideshima, T., et al. (2002) "Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applica-tions", Blood, 99, 4079–4086.
   PubMed Web of Science ®Google Scholar
• Berenson, J.R., Ma, H.M. and Vescio, R. (2001) "The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma", Seminars in Oncology, 28, 626–633.
   Google Scholar
• Shipman, C.M. and Croucher, P.I. (2003) "Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells", Cancer Research, 63, 912–916.
   PubMed Web of Science ®Google Scholar